Clifford V. Harding

Clifford V. Harding

Auto-generated profile, based on publicly available information

Clifford V. Harding

Department of Pathology, Case Western Reserve University and University Hospitals Case Medical Center, Cleveland, Ohio, United States of America

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2010 in Nature Reviews Microbiology
Verified
Journal Article
Closed access
PDF file
CHClifford V. Harding
Clifford V. Harding
WBW. Henry Boom
W. Henry Boom

16 April 2021 in Circulation Research
Verified
Journal Article
Closed access
PDF file
MCMina K. Chung
Mina K. Chung
DZDavid A. Zidar
David A. Zidar
MBMichael R. Bristow
Michael R. Bristow
SCScott J Cameron
Scott J Cameron
TCTimothy Chan
Timothy Chan
JLJoseph Loscalzo
Joseph Loscalzo
A pandemic of historic impact, coronavirus disease 2019 (COVID-19) has potential consequences on the cardiovascular health of millions of people who survive infection worldwide. Severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), the etiologic agent of COVID-19, can infect the heart, vascular tissues, and circulating cells through ACE2 (angiotensin-converting enzyme 2), the host cell receptor for the viral spike protein. Acute cardiac injury is a common extrapulmonary manifestation of COVID-19 with potential chronic consequences. This update provides a review of the clinical manifestations of cardiovascular involvement, potential direct SARS-CoV-2 and indirect immune response mechanisms impacting the cardiovascular system, and implications for the management of patients after recovery from acute COVID-19 infection.

1 April 2012 in The Journal of Immunology
Verified
Journal Article
Closed access
PDF file
DSDaimon P. Simmons
Daimon P. Simmons
PWPamela A Wearsch
Pamela A Wearsch
DCDavid H. Canaday
David H. Canaday
HMHoward J. Meyerson
Howard J. Meyerson
YLYi C. Liu
Yi C. Liu
CHClifford V. Harding
Clifford V. Harding
Microbial molecules or cytokines can stimulate dendritic cell (DC) maturation, which involves DC migration to lymph nodes and enhanced presentation of Ag to launch T cell responses. Microbial TLR agonists are the most studied inducers of DC maturation, but type I IFN (IFN-I) also promotes DC maturation. In response to TLR stimulation, DC maturation involves a burst of Ag processing with enhanced expression of peptide–class II MHC complexes and costimulator molecules. Subsequently, class II MHC (MHC-II) synthesis and expression in intracellular vacuolar compartments is inhibited, decreasing Ag processing function. This limits presentation to a cohort of Ags kinetically associated with the maturation stimulus and excludes presentation of Ags subsequently experienced by the DC. In contrast, our studies show that IFN-I enhances DC expression of MHC-II and costimulatory molecules without a concomitant inhibition of subsequent MHC-II synthesis and Ag processing. Expression of mRNA for MHC-II and the transcription factor CIITA is inhibited in DCs treated with TLR agonists but maintained in cells treated with IFN-I. After stimulation with IFN-I, MHC-II expression is increased on the plasma membrane but is also maintained in intracellular vacuolar compartments, consistent with sustained Ag processing function. These findings suggest that IFN-I drives a distinctive DC maturation program that enhances Ag presentation to T cells without a shutdown of Ag processing, allowing continued sampling of Ags for presentation.

20 February 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
GHGareth A D Hardy
Gareth A D Hardy
SSScott Sieg
Scott Sieg
BRBenigno Rodriguez
Benigno Rodriguez
DADonald Anthony
Donald Anthony
RARobert Asaad
Robert Asaad
CHClifford V Harding
Clifford V Harding
Type-I interferon (IFN-I) has been increasingly implicated in HIV-1 pathogenesis. Various studies have shown elevated IFN-I and an IFN-I-induced gene and protein expression signature in HIV-1 infection, yet the elevated IFN-I species has not been conclusively identified, its source remains obscure and its role in driving HIV-1 pathogenesis is controversial. We assessed IFN-I species in plasma by ELISAs and bioassay, and we investigated potential sources of IFN-I in blood and lymph node tissue by qRT-PCR. Furthermore, we measured the effect of therapeutic administration of IFNα in HCV-infected subjects to model the effect of IFNα on chronic immune activation. IFN-I bioactivity was significantly increased in plasma of untreated HIV-1-infected subjects relative to uninfected subjects (p = 0.012), and IFNα was the predominant IFN-I subtype correlating with IFN-I bioactivity (r = 0.658, p<0.001). IFNα was not detectable in plasma of subjects receiving anti-retroviral therapy. Elevated expression of IFNα mRNA was limited to lymph node tissue cells, suggesting that peripheral blood leukocytes are not a major source of IFNα in untreated chronic HIV-1 infection. Plasma IFN-I levels correlated inversely with CD4 T cell count (p = 0.003) and positively with levels of plasma HIV-1 RNA and CD38 expression on CD8 T cells (p = 0.009). In hepatitis C virus-infected subjects, treatment with IFN-I and ribavirin increased expression of CD38 on CD8 T cells (p = 0.003). These studies identify IFNα derived from lymph nodes, rather than blood leukocytes, as a possible source of the IFN-I signature that contributes to immune activation in HIV-1 infection.

1 January 2009 in Cellular Immunology
Verified
Journal Article
Closed access
MDMichael G. Drage
Michael G. Drage
NPNicole D. Pecora
Nicole D. Pecora
AHAmy G. Hise
Amy G. Hise
MFMaria Febbraio
Maria Febbraio
RSRoy L. Silverstein
Roy L. Silverstein
CHClifford V. Harding
Clifford V. Harding

8 August 2010 in Nature Structural & Molecular Biology
Verified
Journal Article
Open access
PDF file
MDMichael G Drage
Michael G Drage
HTHan-Chun Tsai
Han-Chun Tsai
NPNicole D Pecora
Nicole D Pecora
TCTan-Yun Cheng
Tan-Yun Cheng
AAAhmad R Arida
Ahmad R Arida
CHClifford V Harding
Clifford V Harding
Toll-like receptor 2 is activated by triacylated lipoproteins, but structural and functional studies now show that Mycobacterium tuberculosis lipoprotein LprG is a TLR2 agonist even when it is non-acylated. LprG contains a hydrophobic pocket to bind triacylated glycolipids and delivers them to TLR2, perhaps via CD14. In addition, LprG may serve as a glycolipid chaperone in cell wall assembly by Mycobacterium tuberculosis. Knockout of lprG results in decreased virulence of Mycobacterium tuberculosis (MTB) in mice. MTB lipoprotein LprG has TLR2 agonist activity, which is thought to be dependent on its N-terminal triacylation. Unexpectedly, here we find that nonacylated LprG retains TLR2 activity. Moreover, we show LprG association with triacylated glycolipid TLR2 agonists lipoarabinomannan, lipomannan and phosphatidylinositol mannosides (which share core structures). Binding of triacylated species was specific to LprG (not LprA) and increased LprG TLR2 agonist activity; conversely, association of glycolipids with LprG enhanced their recognition by TLR2. The crystal structure of LprG in complex with phosphatidylinositol mannoside revealed a hydrophobic pocket that accommodates the three alkyl chains of the ligand. In conclusion, we demonstrate a glycolipid binding function of LprG that enhances recognition of triacylated MTB glycolipids by TLR2 and may affect glycolipid assembly or transport for bacterial cell wall biogenesis.